The Covid-19 pandemic’s rapid spread across the world demanded a quick, collaborative response. Now, experts are asking how they can take the lessons from combating Covid-19 and apply them to diseases like cancer.
“As we look at Covid and the lessons we’re learning in the last year-and-a-half, it certainly is a lesson of successes and failures,” said John Oyler, CEO of BeiGene, in an event at the Milken Institute Future of Health Summit this week. “I strongly believe in oncology that we can and will learn from this set of experiences.”
The oncology community has already had to learn some of those lessons on the fly, as Covid-19 restrictions forced more patient care and clinical trials to be conducted remotely. Many researchers didn’t have the background or technology needed to carry out virtual assessments.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect